A New York federal judge has confirmed an arbitration award in favor of California-based Aadi Bioscience Inc., effectively dismissing a claim exceeding $15 million brought by Hong Kong’s EOC Pharma (Hong Kong) Limited. The decision underscores the judiciary’s role in upholding arbitration outcomes, particularly when one party fails to engage in the legal process.
The dispute originated from a licensing agreement between Aadi Bioscience and EOC Pharma concerning the marketing of a new cancer drug in China. EOC Pharma initiated arbitration proceedings, alleging breaches of contract and seeking damages surpassing $15 million. The arbitration panel, however, ruled in favor of Aadi Bioscience, rejecting EOC Pharma’s claims.
Subsequently, Aadi Bioscience petitioned the U.S. District Court for the Southern District of New York to confirm the arbitration award. EOC Pharma did not respond to the petition. In his ruling, Judge John G. Koeltl stated that there was no genuine dispute due to EOC Pharma’s lack of response, thereby granting Aadi Bioscience’s request to enforce the arbitration award. The case details are available on Justia’s docket report: Aadi Bioscience, Inc. v. EOC Pharma (Hong Kong) Limited.
This case highlights the importance of active participation in legal proceedings. EOC Pharma’s failure to respond to the petition led to the court’s decision to confirm the arbitration award without opposition. It also reflects the judiciary’s deference to arbitration as a means of resolving commercial disputes, reinforcing the enforceability of arbitration awards under the Federal Arbitration Act.
Legal professionals should note the critical role of timely responses in arbitration-related litigation. The court’s decision serves as a reminder that non-participation can result in unfavorable outcomes, emphasizing the necessity for parties to engage fully in the arbitration and subsequent enforcement processes.